
Nicolas Verheyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1155835/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. Cell Metabolism, 2019, 30, 462-476.e6.	16.2	256
2	Vitamin D and cardiovascular disease prevention. Nature Reviews Cardiology, 2016, 13, 404-417.	13.7	250
3	Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. Frontiers in Endocrinology, 2018, 9, 373.	3.5	249
4	Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors. Hypertension, 2015, 65, 1195-1201.	2.7	152
5	Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism: Clinical and Experimental, 2014, 63, 20-31.	3.4	133
6	Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-κB. Journal of the American Society of Nephrology: JASN, 2018, 29, 1636-1648.	6.1	109
7	Vitamin-D concentrations, cardiovascular risk and events - a review of epidemiological evidence. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 259-272.	5.7	59
8	The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review. International Journal of Endocrinology, 2017, 2017, 1-12.	1.5	55
9	Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial. American Heart Journal, 2020, 221, 39-47.	2.7	43
10	Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial. Nutrients, 2017, 9, 432.	4.1	39
11	Circulating uromodulin inhibits vascular calcification by interfering with pro-inflammatory cytokine signalling. Cardiovascular Research, 2021, 117, 930-941.	3.8	38
12	Vitamin D: Current Guidelines and Future Outlook. Anticancer Research, 2018, 38, 1145-1151.	1.1	37
13	Vitamin D supplementation and lipoprotein metabolism: A randomized controlled trial. Journal of Clinical Lipidology, 2018, 12, 588-596.e4.	1.5	36
14	Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin—A Randomized Placebo ontrolled Trial. Journal of Clinical Hypertension, 2016, 18, 608-613.	2.0	34
15	Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial. Nutrients, 2017, 9, 623.	4.1	33
16	Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. ESC Heart Failure, 2019, 6, 146-153.	3.1	32
17	Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opinion on Pharmacotherapy, 2013, 14, 793-806.	1.8	31
18	Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-NaÃ ⁻ ve Patients With Hypertension. Hypertension, 2015, 65, 1231-1237.	2.7	31

NICOLAS VERHEYEN

#	Article	IF	CITATIONS
19	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wiener Klinische Wochenschrift, 2020, 132, 742-761.	1.9	31
20	Vitamin D and Mortality. Anticancer Research, 2016, 36, 1379-87.	1.1	28
21	Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocrine Disorders, 2012, 12, 19.	2.2	24
22	Homoarginine/ADMA ratio and homoarginine/SDMA ratio as independent predictors of cardiovascular mortality and cardiovascular events in lower extremity arterial disease. Scientific Reports, 2018, 8, 14197.	3.3	24
23	Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism. Journal of Hypertension, 2016, 34, 1347-1356.	0.5	22
24	Vitamin D Supplementation and Hemoglobin Levels in Hypertensive Patients: A Randomized Controlled Trial. International Journal of Endocrinology, 2016, 2016, 1-7.	1.5	19
25	Exercise training in patients with a left ventricular assist device (Exâ€VAD): rationale and design of a multicentre, prospective, assessorâ€blinded, randomized, controlled trial. European Journal of Heart Failure, 2019, 21, 1152-1159.	7.1	19
26	Effects of vitamin D supplementation on FGF23: a randomized-controlled trial. European Journal of Nutrition, 2019, 58, 697-703.	3.9	19
27	Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism. Journal of Hypertension, 2016, 34, 1778-1786.	0.5	17
28	Beneficial Effects of UV-Radiation: Vitamin D and beyond. International Journal of Environmental Research and Public Health, 2016, 13, 1028.	2.6	16
29	Prevalence and prognostic factors for aortic dilatation in giant cell arteritis – a longitudinal study. Seminars in Arthritis and Rheumatism, 2021, 51, 911-918.	3.4	16
30	Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1034-1042.	2.3	15
31	Intermittent Fasting (Alternate Day Fasting) in Healthy, Non-obese Adults: Protocol for a Cohort Trial with an Embedded Randomized Controlled Pilot Trial. Advances in Therapy, 2018, 35, 1265-1283.	2.9	15
32	Plasma parathyroid hormone and cardiovascular disease in treatmentâ€naive patients with primary hyperparathyroidism: The <scp>EPATH</scp> trial. Journal of Clinical Hypertension, 2017, 19, 1173-1180.	2.0	14
33	Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure. Current Medicinal Chemistry, 2019, 26, 2865-2878.	2.4	13
34	Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. PLoS ONE, 2017, 12, e0173799.	2.5	10
35	Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data. Hormone and Metabolic Research, 2018, 50, 375-382.	1.5	10
36	Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. Kidney and Blood Pressure Research, 2017, 42, 774-783.	2.0	9

NICOLAS VERHEYEN

#	Article	IF	CITATIONS
37	Age-dependent effects of homocysteine and dimethylarginines on cardiovascular mortality in claudicant patients with lower extremity arterial disease. Heart and Vessels, 2018, 33, 1453-1462.	1.2	9
38	Expression Profiles of miR-22-5p and miR-142-3p Indicate Hashimoto's Disease and Are related to Thyroid Antibodies. Genes, 2022, 13, 171.	2.4	9
39	Homoarginine in Patients With Primary Hyperparathyroidism. American Journal of the Medical Sciences, 2015, 349, 306-311.	1.1	8
40	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism – The randomized, placebo-controlled EPATH trial. Bone, 2017, 105, 212-217.	2.9	8
41	DXA-Derived Indices in the Characterisation of Sarcopenia. Nutrients, 2022, 14, 186.	4.1	8
42	The importance of assays in vitamin D status classification: a comparison of four automated 25-hydroxyvitamin D immunoassays. Laboratoriums Medizin, 2013, 37, 261-268.	0.6	7
43	Diagnostic Accuracy of the Aldosterone–to–Active Renin Ratio for Detecting Primary Aldosteronism. Journal of the Endocrine Society, 2019, 3, 1748-1758.	0.2	6
44	Indications and Outcome in Patients Undergoing Left Atrial Appendage Closure—The Austrian LAAC Registry. Journal of Clinical Medicine, 2020, 9, 3274.	2.4	6
45	Associations of Serum Cortisol with Cardiovascular Risk and Mortality in Patients Referred to Coronary Angiography. Journal of the Endocrine Society, 2021, 5, bvab017.	0.2	6
46	The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance. International Journal of Endocrinology, 2018, 2018, 1-2.	1.5	5
47	The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension. PLoS ONE, 2019, 14, e0212973.	2.5	5
48	Myocardial Deformation Analysis in MYBPC3 and MYH7 Related Sarcomeric Hypertrophic Cardiomyopathy—The Graz Hypertrophic Cardiomyopathy Registry. Genes, 2021, 12, 1469.	2.4	5
49	Strain Analysis by Tissue Doppler Imaging: Comparison of Conventional Manual Measurement with a Semiautomated Approach. Echocardiography, 2016, 33, 372-378.	0.9	3
50	Associations of Thyroid Hormones and Resting Heart Rate in Patients Referred to Coronary Angiography. Hormone and Metabolic Research, 2020, 52, 850-855.	1.5	3
51	Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio. ESC Heart Failure, 2021, 8, 3397-3402.	3.1	3
52	Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography. American Journal of Cardiology, 2020, 127, 9-15.	1.6	2
53	Lancisi sign in a 69-year-old man with severe tricuspid regurgitation. Cmaj, 2018, 190, E17-E17.	2.0	1
54	Worsening HeartÂFailure After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, e253-e255.	2.9	1

NICOLAS VERHEYEN

#	Article	IF	CITATIONS
55	Thermic sealing in femoral catheterization: First experience with the Secure Device. Cardiology Journal, 2019, 26, 233-240.	1.2	1
56	Are soluble ST2 levels influenced by vitamin D and/or the seasons?. Endocrine Connections, 2019, 8, 691-700.	1.9	1
57	Myocardial GLP-1 Receptor Activation in the Presence of Glucose: Strong Partners. International Journal of Peptide Research and Therapeutics, 2019, 25, 605-612.	1.9	Ο
58	Stork leg sign in acute pericarditis. Polish Archives of Internal Medicine, 2020, 130, 683-684.	0.4	0